SGP
SpyGlass Pharma, Inc.
34.97
+0.79 (+2.31%)
52w low 17.06
39.92 high
78.3% of range
Financial Analysis
| (USD) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Total Revenue | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | -- | 9.30M | 11.10M | 13.63M | 15.41M | 21.97M | |
| R&D | -- | 7.33M | 8.09M | 7.71M | 8.54M | 10.94M | |
| SG&A | -- | 1.96M | 3.01M | 5.92M | 6.87M | 11.03M | |
| Operating Income | -- | -9.30M | -11.10M | -13.63M | -15.41M | -21.97M | |
| EBITDA | -- | -9.16M | -10.96M | -13.41M | -15.09M | -21.62M | |
| Pretax Income | -- | -8.68M | -9.82M | -12.56M | -13.82M | -19.86M | |
| Income Tax | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -- | -8.68M | -9.82M | -12.56M | -13.82M | -19.86M | |
| EPS Diluted | -0.49 | -0.27 | -- | -- | -0.69 | -0.59 | |
| Diluted Shares | 17.96M | 31.91M | -- | -- | 19.93M | 33.44M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
--